Preclinical CRO + CGT manufacturing proxy. Safety testing creates recurring demand independent of any one drug. Also the best public read on cell/gene therapy manufacturing demand.
Research snapshot · Not reviewed
CRLCharles River Laboratories
Preclinical CRO, CGT manufacturing proxy
Open CRL in Robinhood ↗Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap$11.11BSnapshot value
CGT trial volume (2,000+ in clinic) driving preclinical demand; strategic review (divesting CDMO + Cell Solutions to GI Partners, European Discovery to IQV); CGT manufacturing tailwind.
Strategic review uncertainty; preclinical demand tied to early-stage funding; overlap with Manufacture layer (audit for double-counting); CGT manufacturing mostly private.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🟢 Lean-Bull · ins-$16.9M · 13F 20+/5- · short↑0.33
Snapshot · Not reviewed